The ONE CANCER PLACE NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.
BREAKING NEWS: SURVIVEiT Merges with One Cancer Place
FOR IMMEDIATE RELEASE December 15, 2022 TWO NATIONAL PAN-CANCER PATIENT ADVOCACIES MERGING SURVIVEIT® MERGES WITH ONE CANCER PLACE (Denver, CO) - Two Denver-based cancer patient advocacies have merged...
FDA approves capmatinib for metastatic non-small cell lung cancer
FDA approves capmatinib for metastatic non-small cell lung cancer On August 10, 2022, the Food and Drug Administration granted regular approval to capmatinib (Tabrecta, Novartis Pharmaceuticals Corp.) for adult...
FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma
FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma On April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients...
FDA approves Pluvicto for metastatic castration-resistant prostate cancer
FDA approves Pluvicto for metastatic castration-resistant prostate cancer On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a...
FDA approves pembrolizumab for advanced endometrial carcinoma
FDA approves pembrolizumab for advanced endometrial carcinoma On March 21, 2022, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck), as a single agent, for patients with advanced endometrial carcinoma...
FDA approves Opdualag for unresectable or metastatic melanoma
FDA approves Opdualag for unresectable or metastatic melanoma On March 18, 2022, the Food and Drug Administration approved nivolumab and relatlimab-rmbw (Opdualag, Bristol-Myers Squibb Company) for adult and pediatric patients...
FDA approves olaparib for adjuvant treatment of high-risk early breast cancer
FDA approves olaparib for adjuvant treatment of high-risk early breast cancer On March 11, 2022, the Food and Drug Administration approved olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) for the adjuvant treatment...
FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer
FDA approves neoadjuvant nivolumab and platinum-doublet chemotherapy for early-stage non-small cell lung cancer On March 4, 2022, the Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) with platinum-doublet...
FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma
FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma On February 28, 2022, the Food and Drug Administration approved ciltacabtagene autoleucel (CARVYKTI, Janssen Biotech, Inc.) for the treatment of...
FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma
FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma On January 25, 2022, the Food and Drug Administration approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell...
